Imeglimin may improve albuminuria associated with partial suppression of inflammatory and fibrotic markers in diabetic kidney disease

Yoshimi Muta, Hisashi Yokomizo, Takako Kawanami, Yuriko Hamaguchi, Dai Nagata, Mayuko Yamamoto, Yuki Senda, Yuichi Takashi, Shohta Kodama, Daiji Kawanami · 2026

Read Imeglimin may improve albuminuria associated with partial suppression of inflammatory and fibrotic markers in diabetic kidney disease by Yoshimi Muta, Hisashi Yokomizo, Takako Kawanami, Yuriko Hamaguchi, Dai Nagata, Mayuko Yamamoto, Yuki Senda, Yuichi Takashi, Shohta Kodama, Daiji Kawanami (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13619504.txt.

Description

Yoshimi Muta and nine co-authors test a diabetes drug for kidney protection in a 2026 study with mice and lab cells. The drug, imeglimin, lowers blood sugar and is sold in Japan, but its effect on diabetic kidney disease was unclear. Kidney disease in diabetes shows up early as protein leaking into urine.

In diabetic mice, the drug cut that protein leak without clearly changing blood sugar. Gene checks in kidney tissue showed more activity in protective pathways and less in inflammation and scarring pathways. Scarring in the kidney also fell. In lab cells stressed by high sugar, the drug lowered several harmful signals. The authors suggest the drug helps the kidney in part by calming inflammation.

Catalog record

CREATORYoshimi Muta, Hisashi Yokomizo, Takako Kawanami, Yuriko Hamaguchi, Dai Nagata, Mayuko Yamamoto, Yuki Senda, Yuichi Takashi, Shohta Kodama, Daiji Kawanami
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE31 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC13619504

Browse the full library · About the Tower of Babel